Single-Cell Proteomics Analysis of Recurrent Low-Grade Serous Ovarian Carcinoma and Associated Brain Metastases.
brain metastases
cyclic immunofluorescence
low-grade serous ovarian cancer
single-cell proteomics
spatial analysis
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
24
03
2022
accepted:
20
04
2022
entrez:
13
6
2022
pubmed:
14
6
2022
medline:
14
6
2022
Statut:
epublish
Résumé
Between 2% and 6% of epithelial ovarian cancer (EOC) patients develop brain metastases (brain mets), which are incurable and invariably result in death. This poor outcome is associated with a lack of established guidelines for the detection and treatment of brain mets in EOC patients. In this study, we characterize an unusual case of low-grade serous ovarian carcinoma (LGSOC) that metastasized to the brain. Using a spatially oriented single-cell proteomics platform, we compared sequential biopsies of a primary tumor with a peritoneal recurrence and brain mets. We identified several targetable oncogenic pathways and immunosuppressive mechanisms that are amplified in the brain mets and could be involved in the progression of LGSOC to the brain. Furthermore, we were able to identify cell populations that are shared between the primary tumor and the brain mets, suggesting that cells that have a propensity for metastasis to the brain could be identified early during the course of disease. Taken together, our findings further a path for personalized therapeutic decisions in LGSOC.
Identifiants
pubmed: 35692807
doi: 10.3389/fonc.2022.903806
pmc: PMC9174542
doi:
Types de publication
Journal Article
Langues
eng
Pagination
903806Informations de copyright
Copyright © 2022 Pejovic, Abate, Ma, Thiessen, Corless, Peterson, Allard-Chamard and Labrie.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Onco Targets Ther. 2015 Dec 16;8:3783-92
pubmed: 26719706
J Cutan Pathol. 2010 Mar;37(3):336-43
pubmed: 19615036
Genes Dev. 2018 Oct 1;32(19-20):1267-1284
pubmed: 30275043
Theranostics. 2019 May 31;9(13):3952-3965
pubmed: 31281524
Curr Cancer Drug Targets. 2012 Mar;12(3):247-59
pubmed: 22229251
Cell Signal. 2020 Apr;68:109539
pubmed: 31935430
Oncogene. 2014 Jun 26;33(26):3451-62
pubmed: 23912459
NPJ Precis Oncol. 2021 Oct 19;5(1):92
pubmed: 34667258
J Cancer. 2020 May 18;11(15):4625-4640
pubmed: 32489480
Front Endocrinol (Lausanne). 2019 Oct 16;10:708
pubmed: 31749762
Brain. 2021 May 7;144(4):1046-1066
pubmed: 33893488
Endocr Relat Cancer. 2021 Nov 11;29(1):R1-R16
pubmed: 34636747
Gynecol Oncol. 2019 Jun;153(3):568-573
pubmed: 30876674
Int J Gynecol Cancer. 2011 Jul;21(5):816-21
pubmed: 21613959
Nat Rev Clin Oncol. 2020 May;17(5):279-299
pubmed: 32080373
Immunity. 2003 Jun;18(6):849-61
pubmed: 12818165
J Surg Oncol. 2001 Nov;78(3):194-200; discussion 200-1
pubmed: 11745806
Nat Commun. 2015 Sep 24;6:8390
pubmed: 26399630
Neurosurg Rev. 2005 Apr;28(2):120-3
pubmed: 15558348
Trends Biochem Sci. 2011 Mar;36(3):133-40
pubmed: 20947357
Clin Dev Immunol. 2011;2011:695834
pubmed: 22013483
Proc Natl Acad Sci U S A. 2018 May 1;115(18):4749-4754
pubmed: 29654146
Int Rev Cell Mol Biol. 2015;320:41-73
pubmed: 26614871
Anticancer Res. 2016 Feb;36(2):523-32
pubmed: 26851006
Ann Rheum Dis. 2013 Apr;72(4):614-20
pubmed: 22915621
J Neurooncol. 2004 Feb;66(3):313-25
pubmed: 15015663
Int Immunol. 2013 Feb;25(2):129-37
pubmed: 23087177
J Hematol Oncol. 2020 Jun 22;13(1):81
pubmed: 32571374
Expert Rev Anticancer Ther. 2015;15(8):893-9
pubmed: 26040191
Oncotarget. 2015 Jun 30;6(18):15966-83
pubmed: 25965826
Cancers (Basel). 2021 Jan 05;13(1):
pubmed: 33466236
Cancers (Basel). 2020 Aug 04;12(8):
pubmed: 32759682
Cancers (Basel). 2020 May 23;12(5):
pubmed: 32456205
Cell. 2018 Sep 6;174(6):1373-1387.e19
pubmed: 30193111
Cell Tissue Res. 2016 Sep;365(3):607-19
pubmed: 27474009
Cell Cycle. 2013 Sep 15;12(18):2937-47
pubmed: 23974114
J Clin Oncol. 2019 Sep 20;37(27):2406-2415
pubmed: 31403866
Clin Cancer Res. 2019 Apr 15;25(8):2392-2402
pubmed: 30463850
Gynecol Oncol. 2019 Jul;154(1):144-149
pubmed: 31113680
Methods Mol Biol. 2020;2055:521-562
pubmed: 31502168
J Neurooncol. 2014 Aug;119(1):1-6
pubmed: 24789253